Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. GOOGL
6. APGE
7. MU
8. DFTX
9. HOOD
10. IBM

Go back to Verrica Pharmaceuticals Achieves Positive Topline Results in Phase 2 Clinical Study of VP-102 in Patients with Common Warts
(NASDAQ: VRCA) Delayed: 5.64 +0.01 (0.18%)
Previous Close $5.63    52 Week High $ 
Open $5.63    52 Week Low $ 
Day High $6.19    P/E N/A 
Day Low $5.63    EPS $ 
Volume 105,090